JIC
BIB icon

Johnson Investment Counsel’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Johnson Investment Counsel’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,000
Closed -$259K – 604
2020
Q4 		$259K Buy
+3,000
New +$232K ﹤0.01% 516

Other funds holding BIB

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
OMC
Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
UMC
United Maritime Capital New York $15.2M AUM 45.42% 1-Year Est. Return
Bank Julius Baer & Co
Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return

Johnson Investment Counsel's BIB Position: Q1 2021 in Review

Johnson Investment Counsel sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q1 2021, closing a stake of 3,000 shares — an estimated $259K sold.

Johnson Investment Counsel first reported a position in BIB in Q4 2020 and held it in 1 quarter. The position peaked at $259K in Q4 2020. 30 funds tracked by Wall St. Rank hold BIB as of Q1 2021.

  • Johnson Investment Counsel reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q1 2021 after selling out during the quarter.
  • Johnson Investment Counsel sold 3,000 ProShares Ultra NASDAQ Biotechnology shares in Q1 2021, an estimated $259K.
  • Johnson Investment Counsel first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2020 and held it in 1 quarter.
  • Johnson Investment Counsel's ProShares Ultra NASDAQ Biotechnology position peaked at $259K in Q4 2020.
  • 30 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2021.

Based on Johnson Investment Counsel's 13F filing for Q1 2021, filed 14 May 2021.